Eli Lilly may not have discovered orexins, but the pharma’s latest acquisition marks increasing momentum for a drug class that’s maturing after years of fine-tuning.

The big question on the minds of Wall Street is …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844